Company Analysis
Sign in

Scilex Holding Company (SCLX)

Nasdaq: SCLX · Biological Products, (No Diagnostic Substances) · Palo Alto, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.1
◀ Past 4.5● Present 3.4▶ Future 4.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Scilex Holding Company’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
11
1 of them in 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
'14'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Semnur Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
8 granted
2 published
Semnur Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
6 published
SCILEX HOLDING COMPANY its own name
US, as the owner printed on each patent
1 granted
1 published
Scilex Holding Company its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 29, 202512,285,485Methods of treating painPharmaceuticalsSemnur Pharmaceuticals, Inc.
Dec 17, 202412,168,000Methods of treating painPharmaceuticalsSCILEX HOLDING COMPANY
Jun 25, 202412,016,867Methods of treating inflammation and/or painPharmaceuticalsSemnur Pharmaceuticals, Inc.
Jun 21, 202211,364,251Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Jun 1, 202111,020,485Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Aug 18, 202010,744,144Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Dec 10, 201910,500,284Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Nov 6, 201810,117,938Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Dec 5, 20179,833,460Pharmaceutical formulationPharmaceuticalsSemnur Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Apr 24, 20252025/0127714ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAINPharmaceuticalsScilex Holding Company
Jan 18, 20242024/0016732ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAINPharmaceuticalsSCILEX HOLDING COMPANY
Nov 23, 20232023/0372328ORAL DELAYED BURST FORMULATION OF LOW-DOSE NALTREXONE AND METHODS FOR TREATING FIBROMYALGIA AND LONG COVIDPharmaceuticalsScilex Holding Company
Nov 24, 20222022/0370476METHODS OF TREATING INFLAMATION AND/OR PAINPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 12,016,867 granted from it
Dec 16, 20212021/0386859PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 12,285,485 granted from it
Feb 25, 20212021/0052605PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 11,364,251 granted from it
Jun 25, 20202020/0197523PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 11,020,485 granted from it
Aug 23, 20182018/0235980PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 10,744,144 granted from it
Jul 5, 20182018/0185494PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 10,117,938 granted from it
Jan 11, 20182018/0008714PHARMACEUTICAL FORMULATIONPharmaceuticalsSemnur Pharmaceuticals, Inc. · patent 10,500,284 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SCLX · research, not advice